Literature DB >> 8795138

Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression.

Z Wang1, L Margulies, D J Hicklin, S Ferrone.   

Abstract

Analysis of melanoma cell lines with abnormalities in HLA Class I antigen expression has identified two serological phenotypes caused by distinct molecular defects. One is characterized by lack of HLA Class I antigen expression which is not induced by IFN-gamma or by incubation at 25 degrees C for 24 hrs. This phenotype reflects structural changes in the beta(2)m gene which interfere with its transcription and/or translation or result in the synthesis of a defective beta(2)-mu polypeptide unable to associate with HLA Class I heavy chains. The other phenotype manifests very low HLA Class I antigen expression which is enhanced by IFN-gamma or by incubation at 25 degrees C for 24 hrs. This phenotype reflects abnormalities in TAP heterodimer expression, which cause defects in stable assembly and intracellular transport of the HLA Class I antigen trimolecular complex. Loss of HLA Class I antigens renders melanoma cells resistant to lysis by HLA Class I antigen-restricted cytotoxic T cells which specifically recognize melanoma associated antigens. Therefore, abnormalities in HLA Class I antigen expression may have a negative impact on the outcome of T cell based immunotherapy. Characterization of the molecular defects underlying loss of HLA Class I antigens may suggest approaches to restore their expression. Inclusion of these approaches in the protocols of T cell based immunotherapy may improve its efficacy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8795138     DOI: 10.1111/j.1399-0039.1996.tb02573.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  10 in total

1.  Development of melanoma-targeted polymer micelles by conjugation of a melanocortin 1 receptor (MC1R) specific ligand.

Authors:  Natalie M Barkey; Narges K Tafreshi; Jatinder S Josan; Channa R De Silva; Kevin N Sill; Victor J Hruby; Robert J Gillies; David L Morse; Josef Vagner
Journal:  J Med Chem       Date:  2011-11-10       Impact factor: 7.446

Review 2.  Cancer gene and immunotherapy: recent developments.

Authors:  P Jantscheff; R Herrmann; C Rochlitz
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

3.  Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma.

Authors:  Daniel L Faden; Fernando Concha-Benavente; Anish B Chakka; Elizabeth L McMichael; Uma Chandran; Robert L Ferris
Journal:  Head Neck       Date:  2019-03-04       Impact factor: 3.147

4.  High GILT Expression and an Active and Intact MHC Class II Antigen Presentation Pathway Are Associated with Improved Survival in Melanoma.

Authors:  Kenneth H Buetow; Lydia R Meador; Hari Menon; Yih-Kuang Lu; Jacob Brill; Haiyan Cui; Denise J Roe; David J DiCaudo; K Taraszka Hastings
Journal:  J Immunol       Date:  2019-10-07       Impact factor: 5.422

Review 5.  Disulfide reduction in the endocytic pathway: immunological functions of gamma-interferon-inducible lysosomal thiol reductase.

Authors:  Karen Taraszka Hastings; Peter Cresswell
Journal:  Antioxid Redox Signal       Date:  2011-04-20       Impact factor: 8.401

6.  beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.

Authors:  D J Hicklin; Z Wang; F Arienti; L Rivoltini; G Parmiani; S Ferrone
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

7.  Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells.

Authors:  Z Wang; F M Marincola; L Rivoltini; G Parmiani; S Ferrone
Journal:  J Exp Med       Date:  1999-07-19       Impact factor: 14.307

8.  Biosynthesis of HLA-C heavy chains in melanoma cells with multiple defects in the expression of HLA-A, -B, -C molecules.

Authors:  A Martayan; R Fraioli; E Giorda; A Setini; G Ciccarelli; L Delfino; G B Ferrara; P Giacomini
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

9.  Neoantigen Fitness Model Predicts Lower Immune Recognition of Cutaneous Squamous Cell Carcinomas Than Actinic Keratoses.

Authors:  Elizabeth S Borden; Paul Kang; Heini M Natri; Tanya N Phung; Melissa A Wilson; Kenneth H Buetow; Karen Taraszka Hastings
Journal:  Front Immunol       Date:  2019-11-29       Impact factor: 7.561

10.  High GILT Expression Is Associated with Improved Survival in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition.

Authors:  Anngela C Adams; Elizabeth S Borden; Anne M Macy; Nick Thomson; Haiyan Cui; Mark I Gimbel; Melissa A Wilson; Kenneth H Buetow; Denise J Roe; David J DiCaudo; Jade Homsi; Karen Taraszka Hastings
Journal:  Cancers (Basel)       Date:  2022-04-28       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.